Trial Profile
A Phase I/II Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Linsitinib (Primary) ; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma; OSI Pharmaceuticals
- 14 Feb 2018 Results (n=152) of the phase 2 study evaluating efficacy and tolerability of linsitinib in combination with paclitaxel in patients with recurrent/relapsed epithelial ovarian cancer published in the Gynecologic Oncology
- 06 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.